[Federal Register Volume 69, Number 17 (Tuesday, January 27, 2004)]
[Notices]
[Pages 3955-3956]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E4-116]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-34655]


Notice of Finding of No Significant Impact and Availability of 
Environmental Assessment for Amendment of Materials License No. 37-
30433-01, OSI Pharmaceuticals, Inc.

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability of environmental assessment and finding 
of no significant impact.

-----------------------------------------------------------------------

[[Page 3956]]


FOR FURTHER INFORMATION CONTACT: Betsy Ullrich, Nuclear Materials 
Safety Branch 2, Division of Nuclear Materials Safety, Region I, 475 
Allendale Road, King of Prussia, Pennsylvania 19406, telephone (610) 
337-5040, fax (610) 337-5269; or by e-mail: [email protected].

SUPPLEMENTARY INFORMATION: 

I. Introduction

    The U.S. Nuclear Regulatory Commission (NRC) is considering the 
issuance of a license amendment to OSI Pharmaceuticals, Inc. for 
Materials License No. 37-30433-01, to authorize release of its facility 
in Horsham, Pennsylvania for unrestricted use and has prepared an 
Environmental Assessment (EA) in support of this action in accordance 
with the requirements of 10 CFR part 51. Based on the EA, the NRC has 
concluded that a Finding of No Significant Impact (FONSI) is 
appropriate.

II. EA Summary

    The purpose of the proposed action is to allow for the release of 
the licensee's Horsham, Pennsylvania facility for unrestricted use. OSI 
Pharmaceuticals, Inc. was authorized by NRC from March 9, 1998, to use 
radioactive materials for research and development purposes at the 
site. On July 10, 2003, OSI Pharmaceuticals, Inc. requested that NRC 
release the facility for unrestricted use. OSI Pharmaceuticals, Inc. 
has conducted surveys of the facility and determined that the facility 
meets the license termination criteria in subpart E of 10 CFR part 20.

III. Finding of No Significant Impact

    The NRC staff has evaluated OSI Pharmaceuticals, Inc.'s request and 
the results of the surveys and has concluded that the completed action 
complies with the criteria in subpart E of 10 CFR part 20. The staff 
has prepared the EA (summarized above) in support of the proposed 
license amendment to terminate the license and release the facility for 
unrestricted use. The staff has found that the environmental impacts 
from the proposed action are bounded by the impacts evaluated by the 
``Generic Environmental Impact Statement in Support of Rulemaking on 
Radiological Criteria for License Termination of NRC-Licensed 
Facilities'' (NUREG-1496). On the basis of the EA, the NRC has 
concluded that the environmental impacts from the proposed action are 
expected to be insignificant and has determined not to prepare an 
environmental impact statement for the proposed action.

IV. Further Information

    The EA and the documents related to this proposed action, including 
the application for the license amendment and supporting documentation, 
are available for inspection at NRC's Public Electronic Reading Room at 
http://www.nrc.gov/reading-rm.html (ADAMS Accession Nos. ML031970551, 
ML032340661 and ML040150859). These documents are also available for 
inspection and copying for a fee at the Region I Office, 475 Allendale 
Road, King of Prussia, Pennsylvania, 19406. Persons who do not have 
access to ADAMS, should contact the NRC PDR Reference staff by 
telephone at 1-800-397-4209 or (301) 415-4737, or by e-mail to 
[email protected].

    Dated in King of Prussia, Pennsylvania this 15th day of January, 
2004.

    For the Nuclear Regulatory Commission.
John D. Kinneman,
Chief, Nuclear Materials Safety Branch 2, Division of Nuclear Materials 
Safety, Region I.
 [FR Doc. E4-116 Filed 01-26-04;8:45 am]
BILLING CODE 7590-01-P